EUDA Health to Launch EUDA Helixé 2.0 in January 2026

Rhea-AI Summary

EUDA Health (NASDAQ: EUDA) will launch EUDA Helixé 2.0 in January 2026 as an upgraded premium vitality and longevity supplement.

Key changes include a 20% increase in New Zealand deer placenta powder (from 100 mg to 120 mg), replacement of L-glutathione with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent), advanced preservation and delivery methods (freeze drying, refining, nitrogen encapsulation, and nano emulsification replacing enteric coating), a new proprietary bottle design, and New Zealand Halal certification to enable broader Muslim-market distribution.

Positive

• Deer placenta dose +20% (100 mg to 120 mg)
• New Zealand Halal certification enables Muslim-market distribution
• Nano emulsification replaces enteric coating to improve bioavailability

Negative

• None.

News Market Reaction

-4.49%

7 alerts

-4.49% News Effect

+5.9% Peak Tracked

-3.1% Trough Tracked

-$5M Valuation Impact

$99M Market Cap

0.1x Rel. Volume

On the day this news was published, EUDA declined 4.49%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.9% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $99M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Deer placenta increase: 20% increase Original dosage: 100 mg New dosage: 120 mg +2 more

5 metrics

Deer placenta increase 20% increase Formulation strength enhancement for EUDA Helixé 2.0

Original dosage 100 mg Prior New Zealand deer placenta powder per serving

New dosage 120 mg Updated New Zealand deer placenta powder per serving

Vitamin E content 1.4 mg equivalent D-alpha-tocopherol replacing L-glutathione in formulation

Launch timing January 2026 Planned market launch of EUDA Helixé 2.0

Market Reality Check

Price: $0.8400 Vol: Volume 571,181 is below t...

normal vol

$0.8400 Last Close

Volume Volume 571,181 is below the 20-day average of 650,840, indicating no unusual trading activity ahead of this launch announcement. normal

Technical Shares at $2.45 are trading below the $3.00 200-day moving average, reflecting a weaker longer-term trend before this news.

Peers on Argus

Peers showed mixed moves, with NYC up 5.96%, RFL up 3.45%, while OMH and DUO dec...

Peers showed mixed moves, with NYC up 5.96%, RFL up 3.45%, while OMH and DUO declined and CHG was flat. This contrasts with EUDA’s pre-news decline, pointing to a stock-specific move rather than a broad sector trend.

Historical Context

5 past events · Latest: Dec 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 23	Stem cell platform launch	Positive	+41.2%	Launch of stem cell therapy platform and first longevity clinic in Shenzhen.
Dec 22	QB token integration	Positive	-51.4%	Integration of QB utility token into digital health and rewards platform.
Dec 08	QB token plans	Positive	+8.5%	Plans to integrate QB token and hold it in a digital asset treasury.
Dec 05	Convertible warrant financing	Negative	-6.8%	Securities purchase agreement for a convertible warrant to fund expansion.
Oct 23	India expansion deal	Positive	-15.5%	CK Health Plus partnership to expand Bioenergy therapies and supplements in India.

Pattern Detected

Recent news has triggered both sharp rallies and selloffs, with strategic growth and partnership updates sometimes met with negative price reactions.

Recent Company History

Over the past months, EUDA has announced several strategic initiatives, including a comprehensive stem cell therapy platform and a new longevity clinic in Shenzhen on Dec 23, 2025, which coincided with a 41.18% gain. Digital expansion via the QB utility token drew mixed reactions, with implementation news on Dec 22, 2025 followed by a -51.43% move. Financing via a securities purchase agreement and geographic expansion into India also saw negative reactions. Today’s Helixé 2.0 product upgrade fits into this broader longevity and wellness ecosystem build-out.

Market Pulse Summary

This announcement highlights EUDA’s ongoing build-out of its longevity ecosystem, with EUDA Helixé 2...

Analysis

This announcement highlights EUDA’s ongoing build-out of its longevity ecosystem, with EUDA Helixé 2.0 adding a 20% stronger deer placenta dosage and updated ingredient technologies plus New Zealand Halal certification for broader market access. Set against recent stem cell platform launches, QB token integration, and geographic expansion, the upgrade reinforces a multi-pronged growth strategy. Investors may focus on how this premium supplement supports recurring revenue, complements clinic offerings, and interacts with earlier digital health initiatives and financing steps.

Key Terms

freeze drying, nitrogen encapsulation, nano emulsification, enteric coating, +1 more

5 terms

freeze drying technical

"Freeze Drying: Powder-based ingredients are freeze-dried to preserve nutrient potency"

Freeze drying is a preservation method that freezes a product and then removes water by turning ice directly into vapor under low pressure, like how some dried fruits keep shape and flavor after dehydration. For investors, it matters because it can greatly extend a drug or biologic’s shelf life, simplify transport and storage, and satisfy regulatory stability requirements—factors that affect manufacturing costs, supply reliability, product marketability and revenue risk.

nitrogen encapsulation technical

"Nitrogen Encapsulation: Nitrogen protection minimizes oxidation and hydrolysis"

Nitrogen encapsulation is a packaging or manufacturing technique that surrounds a product or ingredient with nitrogen gas—often by filling containers or tiny capsules with nitrogen—to keep oxygen and moisture away. Like storing photos in an airtight box with desiccant to prevent fading, it helps extend shelf life, preserve potency and reduce spoilage or chemical changes. For investors, this can mean lower product waste, stronger quality control, longer sell-by dates and potentially lower regulatory or recall risk, which affect costs and revenue predictability.

nano emulsification technical

"Nano emulsification (Replaced Enteric Coating): Nano-sized formulation improves solubility"

Nano emulsification is a manufacturing technique that breaks a liquid into extremely tiny droplets—thousands of times smaller than the width of a human hair—so ingredients mix and stay stable in a uniform blend. For investors, it matters because this can make medicines, supplements or topical products more effective, faster-acting or longer-lasting, often allowing lower doses, new formulations, patentable improvements, and potential market or regulatory advantages.

enteric coating technical

"Nano emulsification (Replaced Enteric Coating): Nano-sized formulation improves solubility"

A thin protective layer applied to oral tablets or capsules that prevents them from dissolving in the acidic stomach and lets them release their active ingredient further down the digestive tract. For investors, enteric coating matters because it can change a drug’s effectiveness, safety, manufacturing complexity and cost, regulatory review and patient convenience—similar to a timed envelope that only opens when it reaches the right address.

halal certification regulatory

"EUDA Helixé 2.0 has obtained New Zealand Halal certification"

Halal certification is a formal approval issued by a recognized authority that a product, ingredient or process meets Islamic dietary and ethical rules, including permissible ingredients, hygiene, slaughter methods and supply‑chain controls. For investors, it matters because the certification can increase a product’s market access and sales potential among consumers who require those standards, reduce regulatory and reputational risk, and act like an industry label (similar to organic or kosher) that signals trust and consistency.

AI-generated analysis. Not financial advice.

SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and global market readiness.

Strengthened Formula and Ingredient Optimization

EUDA Helixé 2.0 features a 20% increase in New Zealand sourced deer placenta powder, with dosage enhanced from 100 mg to 120 mg, reinforcing the supplement’s positioning as a high potency vitality formulation. As part of the formulation upgrade, L-glutathione has been replaced with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent). This change is designed to improve antioxidant stability, support cellular protection, enhance skin health and bolster overall youthful vitality, aligning EUDA Helixé 2.0 with long-term wellness and anti-aging objectives.

Advanced Encapsulation and Preservation Technology

EUDA Helixé 2.0 utilizes an upgraded ingredient preservation and delivery platform designed to enhance stability, absorption efficiency, and shelf life:

• Freeze Drying: Powder-based ingredients are freeze-dried to preserve nutrient potency while removing moisture without altering molecular properties.
• Refining Technology: Oil-based ingredients undergo refining to improve stability, reduce allergenic and reactive potential, and increase resistance to heat and light.
• Nitrogen Encapsulation: Nitrogen protection minimizes oxidation and hydrolysis, extending product shelf life.
• Nano emulsification (Replaced Enteric Coating): Nano-sized formulation improves solubility, bioavailability, and absorption speed, allowing efficient nutrient delivery as compared to a traditional enteric coating.

This nano-based delivery system enables EUDA Helixé 2.0 to achieve smaller capsule size and is designed to improve the user experience with efficient nutrient absorption while maintaining or enhancing functional efficacy.

New Proprietary Bottle Design

In conjunction with the product upgrade, EUDA is introducing a new proprietary EUDA Helixé bottle design, reflecting the supplement’s premium positioning while enhancing product protection, shelf presence and brand identity.

New Zealand Halal Certification and Global Market Expansion

EUDA Helixé 2.0 has obtained New Zealand Halal certification, enabling broader international distribution and formal entry into Muslim markets across Southeast Asia, the Middle East and other global regions.

Positioning EUDA Helixé for Global Growth

The upcoming January 2026 launch of EUDA Helixé 2.0 reflects EUDA Health’s commitment to continuous innovation, scientific advancement, and scalable global wellness solutions. With enhanced formulation strength, advanced delivery technology, refined packaging and expanded market accessibility, EUDA Helixé 2.0 is positioned as a core offering within EUDA’s growing health and longevity ecosystem.

Mr Alfred Lim, CEO of EUDA, commented:

“This marks an important milestone in EUDA’s product evolution. With EUDA Helixé 2.0, we are strengthening our core formulation, upgrading delivery technology and expanding global market accessibility through Halal certification. These enhancements reflect our commitment to science-backed innovation and position EUDA Helixé as a premium longevity supplement aligned with EUDA’s broader strategy to scale high-quality wellness solutions globally.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact

Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com

FAQ

When will EUDA launch EUDA Helixé 2.0 (EUDA)?

EUDA Helixé 2.0 is scheduled to launch in January 2026.

What formulation change did EUDA announce for EUDA Helixé 2.0 (EUDA)?

The formula increases New Zealand deer placenta powder by 20% to 120 mg and replaces L-glutathione with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent).

What delivery technology upgrades are included in EUDA Helixé 2.0 (EUDA)?

Upgrades include freeze drying, refining, nitrogen encapsulation, and nano emulsification replacing a traditional enteric coating.

Does EUDA Helixé 2.0 have Halal certification for wider distribution (EUDA)?

Yes. EUDA Helixé 2.0 obtained New Zealand Halal certification to support distribution into Muslim markets.

Will EUDA change packaging for EUDA Helixé 2.0 (EUDA)?

Yes. EUDA is introducing a new proprietary EUDA Helixé bottle design for enhanced protection and premium positioning.

How does EUDA position EUDA Helixé 2.0 within its product strategy (EUDA)?

EUDA positions EUDA Helixé 2.0 as a core premium offering to support its global wellness and longevity growth strategy.